Followers | 85 |
Posts | 3078 |
Boards Moderated | 0 |
Alias Born | 03/03/2010 |
Thursday, September 21, 2023 8:39:41 AM
Recent TVTX News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/06/2024 08:46:22 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2024 08:05:27 PM
- Travere Therapeutics Reports First Quarter 2024 Financial Results • GlobeNewswire Inc. • 05/06/2024 08:01:00 PM
- Travere Therapeutics to Report First Quarter 2024 Financial Results • GlobeNewswire Inc. • 04/29/2024 08:30:00 PM
- Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy • GlobeNewswire Inc. • 04/24/2024 11:05:00 AM
- CSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy • PR Newswire (Canada) • 04/24/2024 07:00:00 AM
- CSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy • PR Newswire (US) • 04/24/2024 07:00:00 AM
- Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders and Genetic Metabolic Dieticians International • GlobeNewswire Inc. • 04/04/2024 08:30:00 PM
- Travere Therapeutics to Present Abstracts on FILSPARI® (sparsentan) in IgA Nephropathy at World Congress of Nephrology and the American Nephrology Nurses Association • GlobeNewswire Inc. • 04/03/2024 08:30:00 PM
- Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 03/13/2024 09:00:00 PM
- Travere Therapeutics Submits Supplemental New Drug Application to the U.S. Food and Drug Administration Seeking Full Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy (IgAN) • GlobeNewswire Inc. • 03/11/2024 11:05:00 AM
- Travere Therapeutics to Present at Upcoming Investor Conferences • GlobeNewswire Inc. • 02/26/2024 09:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/23/2024 09:05:34 PM
- Travere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatment of IgA Nephropathy • GlobeNewswire Inc. • 02/23/2024 12:05:39 PM
- CSL Vifor and Travere Therapeutics announce sparsentan receives positive CHMP opinion for the treatment of IgA nephropathy • PR Newswire (Canada) • 02/23/2024 07:00:00 AM
- CSL Vifor and Travere Therapeutics announce sparsentan receives positive CHMP opinion for the treatment of IgA nephropathy • PR Newswire (US) • 02/23/2024 07:00:00 AM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/20/2024 01:10:04 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/15/2024 09:05:22 PM
- Travere Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results • GlobeNewswire Inc. • 02/15/2024 09:01:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 07:35:11 PM
- Travere Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results • GlobeNewswire Inc. • 02/08/2024 09:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:06:01 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:05:41 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:05:37 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM